BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 27824703)

  • 21. Serum miR-125b is a non-invasive predictive biomarker of the pre-operative chemoradiotherapy responsiveness in patients with rectal adenocarcinoma.
    D'Angelo E; Fassan M; Maretto I; Pucciarelli S; Zanon C; Digito M; Rugge M; Nitti D; Agostini M
    Oncotarget; 2016 May; 7(19):28647-57. PubMed ID: 27081702
    [TBL] [Abstract][Full Text] [Related]  

  • 22. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer.
    Sim SH; Kang MH; Kim YJ; Lee KW; Kim DW; Kang SB; Eom KY; Kim JS; Lee HS; Kim JH
    BMC Cancer; 2014 Apr; 14():241. PubMed ID: 24708484
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of molecular markers as a method to predict the response to neoadjuvant therapy for advanced stage rectal adenocarcinoma.
    Edden Y; Wexner SD; Berho M
    Colorectal Dis; 2012 May; 14(5):555-61. PubMed ID: 21689364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer.
    Kim IJ; Lim SB; Kang HC; Chang HJ; Ahn SA; Park HW; Jang SG; Park JH; Kim DY; Jung KH; Choi HS; Jeong SY; Sohn DK; Kim DW; Park JG
    Dis Colon Rectum; 2007 Sep; 50(9):1342-53. PubMed ID: 17665260
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients.
    Lopes-Ramos CM; Habr-Gama A; Quevedo Bde S; Felício NM; Bettoni F; Koyama FC; Asprino PF; Galante PA; Gama-Rodrigues J; Camargo AA; Perez RO; Parmigiani RB
    BMC Med Genomics; 2014 Dec; 7():68. PubMed ID: 25496125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absence of cyclooxygenase-2 protein expression is a predictor of tumor regression in rectal cancer treated with preoperative short-term chemoradiotherapy.
    Kobayashi H; Hashiguchi Y; Ueno H; Shinto E; Kajiwara Y; Mochizuki H
    Dis Colon Rectum; 2007 Sep; 50(9):1354-62. PubMed ID: 17308999
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of Molecular Pretreated Tumor Profiles as Predictive Biomarkers of Therapeutic Response and Survival Outcomes after Neoadjuvant Therapy for Rectal Cancer in Moroccan Population.
    El Otmani I; El Agy F; El Baradai S; Bouguenouch L; Lahmidani N; El Abkari M; Benajah DA; Toughrai I; El Bouhaddouti H; Mouaqit O; Ibn Majdoub Hassani K; Mazaz K; Benjelloun EB; Ousadden A; El Rhazi K; Bouhafa T; Benbrahim Z; Ouldim K; Ibrahimi SA; Ait Taleb K; Chbani L
    Dis Markers; 2020; 2020():8459303. PubMed ID: 31998419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barium enema and CT volumetry for predicting pathologic response to preoperative chemoradiotherapy in rectal cancer patients.
    Murono K; Kawai K; Tsuno NH; Ishihara S; Yamaguchi H; Sunami E; Kitayama J; Watanabe T
    Dis Colon Rectum; 2014 Jun; 57(6):715-24. PubMed ID: 24807596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating cell-free DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy.
    Agostini M; Pucciarelli S; Enzo MV; Del Bianco P; Briarava M; Bedin C; Maretto I; Friso ML; Lonardi S; Mescoli C; Toppan P; Urso E; Nitti D
    Ann Surg Oncol; 2011 Sep; 18(9):2461-8. PubMed ID: 21416156
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Multigene Model for Predicting Tumor Responsiveness After Preoperative Chemoradiotherapy for Rectal Cancer.
    Cho E; Park IJ; Yeom SS; Hong SM; Lee JB; Kim YW; Kim MJ; Lim HM; Lim SB; Yu CS; Kim JC
    Int J Radiat Oncol Biol Phys; 2019 Nov; 105(4):834-842. PubMed ID: 31419511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Yokoe T; Okugawa Y; Ioue Y; Miki C; Kusunoki M
    Ann Surg Oncol; 2009 Dec; 16(12):3488-98. PubMed ID: 19657699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of Ki67 and p53 in locally advanced rectal cancer: correlation with thymidylate synthase and histopathological tumor regression after neoadjuvant 5-FU-based chemoradiotherapy.
    Jakob C; Liersch T; Meyer W; Becker H; Baretton GB; Aust DE
    World J Gastroenterol; 2008 Feb; 14(7):1060-6. PubMed ID: 18286688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nomogram for prediction of pathologic complete remission using biomarker expression and endoscopic finding after preoperative chemoradiotherapy in rectal cancer.
    Hur H; Cho MS; Koom WS; Lim JS; Kim TI; Ahn JB; Kim H; Kim NK
    Chin J Cancer Res; 2020 Apr; 32(2):228-241. PubMed ID: 32410800
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MicroRNA-21 predicts response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Caramés C; Cristóbal I; Moreno V; del Puerto L; Moreno I; Rodriguez M; Marín JP; Correa AV; Hernández R; Zenzola V; Hernández T; León A; Martín JI; Sánchez-Fayos P; García-Olmo D; Rojo F; Goel A; Fernandez-Aceñero MJ; García-Foncillas J
    Int J Colorectal Dis; 2015 Jul; 30(7):899-906. PubMed ID: 25953218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive factors of tumor shrinkage and histological regression in patients who received preoperative radiotherapy for rectal cancer.
    Suzuki T; Sadahiro S; Fukasawa M; Ishikawa K; Kamijo A; Yasuda S; Makuuchi H; Ohizumi Y; Murayama C
    Jpn J Clin Oncol; 2004 Dec; 34(12):740-6. PubMed ID: 15640505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer.
    Maretto I; Pomerri F; Pucciarelli S; Mescoli C; Belluco E; Burzi S; Rugge M; Muzzio PC; Nitti D
    Ann Surg Oncol; 2007 Feb; 14(2):455-61. PubMed ID: 17139456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p21 does, but p53 does not predict pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Stojanovic-Rundic S; Jankovic R; Micev M; Nikolic V; Popov I; Gavrilovic D; Plesinac-Karapandzic V; Djuric-Stefanovic A; Krivokapic Z; Radulovic S
    J BUON; 2017; 22(6):1463-1470. PubMed ID: 29332339
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene expression profiles of tumor regression grade in locally advanced rectal cancer after neoadjuvant chemoradiotherapy.
    Saigusa S; Tanaka K; Toiyama Y; Matsushita K; Kawamura M; Okugawa Y; Hiro J; Inoue Y; Uchida K; Mohri Y; Kusunoki M
    Oncol Rep; 2012 Sep; 28(3):855-61. PubMed ID: 22711167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncologic outcome after preoperative chemoradiotherapy in patients with pathologic T0 (ypT0) rectal cancer.
    Jang TY; Yu CS; Yoon YS; Lim SB; Hong SM; Kim TW; Kim JH; Kim JC
    Dis Colon Rectum; 2012 Oct; 55(10):1024-31. PubMed ID: 22965400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Pathological Complete Response Using Endoscopic Findings and Outcomes of Patients Who Underwent Watchful Waiting After Chemoradiotherapy for Rectal Cancer.
    Kawai K; Ishihara S; Nozawa H; Hata K; Kiyomatsu T; Morikawa T; Fukayama M; Watanabe T
    Dis Colon Rectum; 2017 Apr; 60(4):368-375. PubMed ID: 28267003
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.